Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†
Authors
Keywords
-
Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 47, Issue 2, Pages 137-144
Publisher
Oxford University Press (OUP)
Online
2016-11-21
DOI
10.1093/jjco/hyw175
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
- (2016) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
- (2016) Patrick Schöffski et al. LANCET
- Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent
- (2015) N. F. Dybdal-Hargreaves et al. CLINICAL CANCER RESEARCH
- Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study
- (2015) Akira Kawai et al. LANCET ONCOLOGY
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) ANNALS OF ONCOLOGY
- Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
- (2014) Patrick Schöffski et al. Oncology Research and Treatment
- Incidence of soft tissue sarcoma and beyond
- (2012) Giuseppe Mastrangelo et al. CANCER
- Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project
- (2012) C.A. Stiller et al. EUROPEAN JOURNAL OF CANCER
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
- (2011) Patrick Schöffski et al. LANCET ONCOLOGY
- Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer1
- (2010) Primo N. Lara et al. CANCER
- Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics forIn vivoEfficacy under Intermittent Dosing Conditions
- (2010) Murray J. Towle et al. CANCER RESEARCH
- Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
- (2009) Jennifer A. Smith et al. BIOCHEMISTRY
- Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics
- (2009) David R. Gandara et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started